# MapLight Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maplight-therapeutics

- Industry: Biotechnology
- Headquarters: Burlington, US
- Website: www.maplightrx.com
- Total disclosed funding: $238M
- Latest round: Series D (Jul 18, 2025)
- Investors on record: 9

## About

Founded in 2018 and based in Massachusetts, US, MapLight Therapeutics, Inc. operates as a biotechnology company that offers drugs to treat neurological and psychiatric disorders. The company was founded by its CEO, Christopher Kroeger, and Robert Malenka. In July 2025, MapLight Therapeutics, Inc. raised USD 372.5 million in series D funding co-led by new investors Goldman Sachs XIG and Fobion, with participation from other new investors Sanofi Ventures, T.Rowe Price Investment Management, and Avego. Returning investors Novo Holdings, 5AM Ventures, and Blue Owl, and other unspecified investors also participated in the round. MapLight Therapeutics develops drugs for people with neurological and neuropsychiatric disorders, including autism spectrum disorder, Parkinson's disease, schizophrenia, dyskinesias, and Alzheimer's disease psychosis. The firm offers a wide range of discovery platforms, including optogenetics, a laboratory technique that identifies cell types in the brain; transcriptomics, a platform that identifies the gene expression pattern of each cell type in the brain; and STARmap, a platform that identifies transcription patterns of each cell type in the brain. The company’s pipeline products include ML-004, a 5HT-1b agonist; ML-007C-MA, a muscarinic agonist; ML-007, a muscarinic receptor agonist; and ML-009. The company plans to use the funds raised in July 2023 to support its next phase of research and development.

## Funding rounds

- Series D, Jul 18, 2025, $188M — Goldman Sachs Asset Management, 5AM Ventures, Novo Holdings, Forbion, Sanofi Ventures, Avego, Blue Owl, T.Rowe Price Investment Management
- Series C, Jul 5, 2023, $50M — 5AM Ventures, Novo Holdings, Cowen Investment Management

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series C, Series D
- Novo Holdings — Series C, Series D
- Cowen Investment Management — Series C
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series D
- Forbion (https://capitalatlas.ai/funds/forbion) — Series D
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series D
- Avego (https://capitalatlas.ai/funds/avego) — Series D
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series D
- T.Rowe Price Investment Management — Series D